title: The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions.
abstract: BACKGROUND
  Peripheral arterial disease is a manifestation of systemic atherosclerosis and is predictive of future cardiovascular events. Clinical trial data have demonstrated that medical therapy can attenuate cardiovascular morbidity and mortality in patients with peripheral arterial disease. The utilization and impact of recommended medical therapy in a contemporary population of patients who undergo percutaneous interventions for lifestyle-limiting peripheral arterial disease is unknown.
  
  
  RESULTS
  Using the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Peripheral Vascular Intervention (BMC2 PVI) database, we identified 1357 peripheral vascular intervention encounters between January 2007 and December 2009 for the purpose of treating claudication. Before the intervention, 85% of these patients used aspirin, 76% used statin, 65% abstained from smoking, and 47% did all 3. There was no difference in cardiovascular events among those taking an aspirin and a statin on admission and those who were not. However, in both an unadjusted and a multivariable analysis, the odds of an adverse peripheral vascular outcome (repeat peripheral intervention, amputation, or limb salvage surgery) within 6 months decreased by more than half in patients receiving aspirin and statin therapy before peripheral vascular intervention as compared with those who received neither (odds ratio, 0.45; 95% CI, 0.29-0.71).
  
  
  CONCLUSIONS
  The fundamental elements of medical therapy in patients with lifestyle-limiting claudication are often underutilized before referral for revascularization. Appropriate medical therapy before percutaneous revascularization is associated with fewer peripheral vascular events at 6 months.
authors.affiliation: Blue Cross Blue Shield of Michigan Cardiovascular Consortium, Department of Internal Medicine, University of Michigan, Ann Arbor, USA.
authors.forename: Amer K
authors.initials: AK
authors.lastname: Ardati
authors.forename: Samuel R
authors.initials: SR
authors.lastname: Kaufman
authors.forename: Herbert D
authors.initials: HD
authors.lastname: Aronow
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Nypaver
authors.forename: Paul G
authors.initials: PG
authors.lastname: Bove
authors.forename: Hitinder S
authors.initials: HS
authors.lastname: Gurm
authors.forename: P Michael
authors.initials: PM
authors.lastname: Grossman
mesh_terms: D000368:Aged; D000671:Amputation, Surgical; D001241:Aspirin / Q000627:therapeutic use*; D054598:Blue Cross Blue Shield Insurance Plans; D016009:Chi-Square Distribution; D057510:Endovascular Procedures / Q000009:adverse effects; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007383:Intermittent Claudication / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D023821:Limb Salvage; D016015:Logistic Models; D008297:Male; D008824:Michigan; D015999:Multivariate Analysis; D016017:Odds Ratio; D058729:Peripheral Arterial Disease / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D016540:Smoking Cessation; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin